Skip to main content
OpenTrials
Completed

NCT Number: NCT00662337

Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride

The purpose of this study is to determine if two formulations of diphenhydramine hydrochloride are bioequivalent.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

Subjects were required to observe a ten-hour fast and a one-hour fluid restriction prior to each dosing period.

Subjects were randomized into one of two active treatment groups, received supervised dosing of their treatment with approximately eight ounces of water, and were required to maintain fluid restriction for one hour after treatment. Following the one-hour post-dose fluid restriction, subjects could drink water, but consumer no other food or fluids for four hours post-dose.

Following a seven-day washout period, the comparison treatment was administered according to the same procedure as above.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy male and/or female subjects between the ages of 18 and 55 years, inclusive
  • approximately 18 to 30 kg/m2 BMI
  • total body weight at least 55 kg (121 lbs)
  • able to understand and sign the written Informed Consent Form
  • willing to follow the protocol requirements and comply with protocol restrictions

Exclusion criteria

  • pregnant or lactating women
  • women of childbearing potential not using acceptable form of contraception 3 months prior to the first dose until completion of follow-up procedures
  • history of allergy, sensitivity, and/or idiosyncratic reaction to Benadryl, diphenhydramine hydrochloride, or diphenhydramine citrate
  • evidence of clinical, dietary or psychiatric deviation from normal that could increase the risk to the subject or research staff or interfere with the interpretation of study results
  • use of licit or illicit drugs
  • participated in any other trials within a specified number of days prior to the first dose of the trial treatment

Treatment and study plan

Diphenhydramine hydrochloride

Drug

After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.

Other names: Benadryl Allergy, 25 mg KAPSEALS capsule, 25 mg ULTRATAB tablets

Primary outcomes

  1. Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUC0-t and AUC0-infinity

    Time frame: At 15 minutes pre-dose (0 hour), and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 36 and 48 hours post-dose

Secondary outcomes

  1. The safety analysis included all subjects who took at least one dose of clinical trial test product and had any follow-up information. Subjects in the safety analysis set were summarized and listed, based on actual treatment received.

    Time frame: 15 minutes pre-dose (0 hour) through 28 days post-dose

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide

Industry

Registry information

Official study title

A Randomized, Two-Way Crossover Evaluation of the Bioequivalence Between Two Oral Formulations of Diphenhydramine: ULTRATAB Tablet Versus KAPSEALS Capsule

Important dates

Study start
2006
Primary completion
2006
Study completion
2006
First posted
Apr 21, 2008
Registry last updated
Sep 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.